Markets

Rare disease biotech Eidos Therapeutics prices IPO at $17, the high end of the range

Eidos Therapeutics, which is developing a novel oral therapy for rare neurodegenerative diseases, raised $106 million by offering 6.25 million shares at $17, the high end of the range of $15 to $17. Eidos Therapeutics plans to list on the Nasdaq under the symbol EIDX. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.

The article Rare disease biotech Eidos Therapeutics prices IPO at $17, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs